DNA vaccine shows promise for Hard-to-Treat hepatitis b
NCT ID NCT00988767
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 27 times
Summary
This early-stage study tested a DNA vaccine for safety in 10 adults with chronic hepatitis B who did not respond to standard treatments. The goal was to see if the vaccine could safely boost the body's immune response against the virus. The study focused on safety and immune system changes, not on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service d'Hepatologie, Hopital Necker Enfants Malades
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.